Robert Rosenson, MD

Robert S. Rosenson, MD, is Professor of Medicine (Cardiology) at the Icahn School of Medicine at Mount Sinai and Director of the Metabolism and Lipids Program for the Mount Sinai Health System. Dr. Rosenson is a Fellow of the American College of Cardiology (FACC), American College of Physicians (FACP), American Heart Association (FAHA) Council on Arteriosclerosis, Thrombosis, and Vascular Biology, AHA Council on Epidemiology and Prevention, European Society of Cardiology (FESC), and National Lipid Association (FNLA).

Dr. Rosenson earned his medical degree from Tulane University in New Orleans, Louisiana where he conducted research on prostaglandin metabolism in coronary arteries. This work was recognized when he was awarded the Querens-Rives-Shore Award for best thesis in Cardiology. He then served his residency in medicine at Brigham and Women’s Hospital in Boston, Massachusetts. He later completed a fellowship in cardiovascular medicine at the University of Chicago that was followed by an additional year of training as a Research Associate in lipoprotein metabolism.

Dr. Rosenson is the recipient of numerous awards and honors, including the Ground-Breaking Doctors Award from Chicago magazine, and was named a New York Top Doc from 2015 to 2024 and a USA Top Doctor in 2019. Dr. Rosenson was the recipient of the Simon Dack Award for outstanding scholarship by the Journal of the American College of Cardiology in 2015, 2016, 2017, 2019, 2020, 2022, 2023, and 2025. The International Academy of Cardiology honored him with the Jan J. Kellerman Memorial Award in 2016 for distinguished contributions in the field of cardiovascular disease prevention. In 2017, UpToDate recognized Dr. Rosenson for 20 years of Outstanding Contributions as Editor. In 2019, he was awarded the Clinician Educator Award from the National Lipid Association. He was selected by the University of Toronto for the “Great Minds and Great Medicine: Isadore Rosenfeld Visiting Lectureship.” He is former co-Editor in Chief for Cardiovascular Drugs and Therapy, Section Editor on Metabolic Disorders for the Journal of the American College of Cardiology, and Section Editor on Lipid Disorders for UptoDate.

Dr. Rosenson is a Diplomate of the American Board of Internal Medicine, with a subspecialty in cardiovascular disease, the National Board of Medical Examiners, and National Lipid Association. He currently serves on a number of committees for professional societies. He has served on nine committees for the American College of Cardiology and as a member of the Expert Document Committee for the American College of Cardiology and ACCF Representative to the ADA Aspirin Therapy in Diabetes Position Statement. He has been extensively involved with the National Lipid Association where he served as a National Board Member and Northeast Lipid Association Board Member. Dr. Rosenson served as Chair of the Statin Safety Expert Muscle Document Committee. Dr. Rosenson led three international working groups on HDL that resulted in seminal articles on HDL nomenclature, HDL and macrophage cholesterol, and HDL function and dysfunction. In 2025, Dr. Rosenson was selected to serve as an ADA Representative of the Peer Review Committee for the 2026 AHA/ACC Guideline for the Management of Blood Cholesterol.

Dr. Rosenson has been involved in numerous grant-supported research investigations studying the effects of lipid-lowering therapy in inflammation, thrombogenesis, and rheology. His laboratory was the first to demonstrate that statins reduce pro-inflammatory cytokine production. He has continued this work through mechanistic studies on inflammatory markers with studies on fenofibrate. He has conducted research with selective inhibitors of inflammatory pathways such as lipoprotein-associated phospholipase A2, and secretory phospholipase A2.

Dr. Rosenson has made important contributions concerning the prognostic significance of lipoprotein subclasses in coronary atherosclerosis, cardiovascular events and prediction of type 2 diabetes. He has served as Principal Investigator on a number of NIH-funded research studies, pharmaceutical-sponsored drug trials, and multicenter studies.

Dr. Rosenson served as the global lead enroller for a phase 2 clinical study evaluating the efficacy, safety, and tolerability of a small mRNA inhibitor (olpasiran) in subjects with elevated lipoprotein(a) [Lp(a)] and atherosclerotic vascular disease. He served as the global lead and steering committee member on multiple clinical studies using PCSK9 inhibitors and multiple subgroup analyses of clinical trial data, global lead for two trials with a human monoclonal antibody to angiopoietin like 3 protein (evinacumab) in patients with refractory hypercholesterolemia and severe hypertriglyceridemia, and contributed as an executive committee member for a phase 3 double-blinded RCT that showed significant and clinically meaningful reductions of LDL-C in patients with homozygous familial hypercholesterolemia. Additionally, Dr. Rosenson served as Global Principal Investigator of the PLASMA I, PLASMA II, FRANCIS, and BANTING trials.

As of August 2025, Dr. Rosenson has authored over 480 peer-review journal articles and over 1,000 book chapters, abstracts, and electronic publications for UpToDate Medicine. In 2024, he was recognized by Clarivate as a Highly Cited Researcher, an accomplishment achieved by only 0.1% of researchers globally.

The state of Florida requires out-of-state professionals who are registered to provide telehealth services to display a hyperlink to the Florida Department of Health telehealth web page. This allows Florida patients who are receiving medical care by telehealth to confirm the provider’s licensure and Florida registration.